NIOX GroupCSSPF 77 Median PS Value is $1.04 as of Jun. 24, 2026, which is 17% above its 10-year median of 0.89. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 337 Medical Devices & Instruments companies, NIOX Group ranks worse than 58.16% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. NIOX Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.154. NIOX Group's 10-Year median PS Ratio is 6.7532. Therefore, the Median PS Value for today is $1.04.
As of today (2026-06-24), NIOX Group's share price is $0.79965. NIOX Group's Median PS Value is $1.04. Therefore, NIOX Group's Price to Median PS Value for today is 0.77.
The historical rank and industry rank for NIOX Group's Median PS Value or its related term are showing as below:
CSSPF'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.77 Med: 0.89 Max: 0.89
Current: 0.77
During the past 13 years, the highest Price to Median PS Value of NIOX Group was 0.89. The lowest was 0.77. And the median was 0.89.
CSSPF's Price-to-Median-PS-Value is ranked worse than 58.16% of 337
companies
in the Medical Devices & Instruments industry
Industry Median: 0.7
vs CSSPF: 0.77
NIOX Group (OTCPK:CSSPF) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
NIOX Group's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.79965
/
1.04
=
0.77
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NIOX Group Median PS Value Related Terms
NIOX Group Median PS Value Historical Data
* Premium members only.
The historical data trend for NIOX Group's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSSPF vs ABT, SYK, MDT: Median PS Value Comparison
For the Medical Devices subindustry, NIOX Group's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group Price-to-Median-PS-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where NIOX Group's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 6.7532.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NIOX Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.154.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NIOX Group (CSSPF) has a Median PS Value of $1.04 as of Jun. 24, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on NIOX Group and its competitors. This is 17% above median its historical median of 0.89. Over the past decade, NIOX Group's Median PS Value has ranged from 0.77 to 0.89. According to the industry distribution chart, NIOX Group ranks #196 out of 337 companies in the Medical Devices & Instruments industry, placing it in the top 58.2%.
Is NIOX Group's Median PS Value too high?
NIOX Group's current Median PS Value of $1.04 is 17% above median its 10-year median of 0.89. Over the past 10 years, this metric has ranged from a low of 0.77 to a high of 0.89. The Medical Devices & Instruments industry median Median PS Value is 0.70. NIOX Group's value of $1.04 is 48.6% above this industry median. Based on the distribution chart, NIOX Group ranks #196 out of 337 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's Median PS Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #196 out of 337 companies for Median PS Value. This places NIOX Group in the lower half of its industry. The industry median Median PS Value is 0.70. NIOX Group's value of $1.04 is 48.6% above this benchmark. Historically, NIOX Group's own Median PS Value has ranged from 0.77 to 0.89 over the past decade. While the company's 10-year median is 0.89 vs. the industry median of 0.70, NIOX Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Devices & Instruments company?
The median Median PS Value among Medical Devices & Instruments companies is 0.70, based on 337 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current Median PS Value of $1.04 is 48.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median Median PS Value is 0.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current Median PS Value is $1.04, which is 17% above median its own 10-year median of 0.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.80 — trading 33.9% below its estimated fair value. The current Median PS Value is $1.04, which is 17% above median its 10-year median of 0.89 and 48.6% above the Medical Devices & Instruments industry median of 0.70. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For NIOX Group (CSSPF), the current Median PS Value is $1.04 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.80 is trading 33.9% below its estimated GF Value™ of $1.21.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
Median PS Value: $1.04 (17% above median its 10-year median of 0.89)
GF Value™: $1.21 vs. price of $0.80 (33.9% below fair value)
Industry Position: 48.6% above the Medical Devices & Instruments median (#196 of 337)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
